Sudeep Pharma block deals, bulk deals, insider trading and stake changes
NSE: SUDEEPPHRMBSE: 544619Chemicals & PetrochemicalsSmall Cap
Share price at the NSE close on 28 Oct 2026. Previous close ₹1,022.40.
28 Oct: open ₹1,030.00, high ₹1,124.60, low ₹1,029.90
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹12,639 Cr654th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 66.92
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 13.20
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.13%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 22.5%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 20.1%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026.
- 0.19
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 8,39,00844.1% delivered
Sudeep Pharma's insiders have 4 trade disclosures on record, the latest on 30 Sep 2026. Its promoter group made no purchase or sale on the market in the 12 months to 28 Oct 2026.
Promoter and insider buying and selling
Trades made since 29 Oct 2025.Sudeep Pharma promoter holding
No promoter, director, key manager or employee bought or sold on the market.
- Others: no market trade · 3 pledge filings of unclear kind
Sudeep Pharma insider trading
Sep 2026
- Mr. Raghunandan Rao₹0.37 Cr3,000 sharesPledge · Designated Person · 2 Sep 2026 · disclosed 30 Sep
- Mr. Raghunandan Rao₹0.39 Cr3,000 sharesSold or invoked · Designated Person · 2 Sep 2026 · disclosed 30 Sep
Feb 2026
- Mr. Raghunandan Rao₹0.15 Cr2,261 sharesPledge · Designated Person · 12 Feb 2026 · disclosed 7 Apr
Dec 2025
- Mr. Raghunandan Rao₹0.11 Cr1,478 sharesPledge · Designated Person · 2 Dec 2025 · disclosed 5 Dec
Trades by the company's promoters, directors, key managers, employees and their relatives, as each disclosed them. Value is what the filer stated; the mode is shown where the shares moved off the market.
Sudeep Pharma stake sales and purchases
All 2 disclosures on record.
Jul 2026
- SoldNuvama Crossover Opportunites Fund-Series III2.40% of the company26,68,118 sharesholds 6.00% after24 Jul 2026 · filed under the 2% rule · Open Market
Nov 2025
- AcquiredNuvama Crossover Opportunites Fund-Series III8.40% of the company94,51,295 sharesholds 8.40% after27 Nov 2025 · filed under the 5% rule · Preferential Allotment
The 5% rule: an investor discloses on reaching 5% of the company. The 2% rule: a holder of 5% or more discloses each change of 2% or more, including one that takes it below 5%. A transfer exempt from an open offer, the offer to buy from every other shareholder that a large purchase otherwise brings, is disclosed too. Each line shows what its filing states, which can be a smaller change than its rule names.
Sudeep Pharma block deals and bulk deals
Last 12 months, since 29 Oct 2025: 6 block deals and 19 bulk deals, ₹1,023 Cr bought and ₹972 Cr sold Bought and sold in deals. Each deal's shares times its price, added up for the buyers and apart for the sellers, so a block deal, which names both, counts on each side.Today's bulk and block deals, all companies
ValueValue of a deal. The shares traded times the deal's price.Per cent of the companyPer cent of the company. The shares traded as a percentage of all the company's shares in issue on the day of the deal.
Tuesday 4 Aug 20265 firms · ₹200 Cr bought · ₹152 Cr soldNet bought ₹48 Cr
- BoughtGOLDMAN SACHS FUNDS - GOLDMAN SACHS INDIA EQUITY PORTFOLIOBlock dealBought 11,76,472 at ₹850.001.04% of the company₹100 Cr
- BoughtGOLDMAN SACHS FUNDS - GOLDMAN SACHS INDIA EQUITY PORTFOLIOBought 11,76,472 at ₹850.001.04% of the company₹100 Cr
- SoldNUVAMA CROSSOVER OPPORTUNITIES FUND - SERIES IIIBlock dealSold 6,14,112 at ₹850.000.54% of the company₹52 Cr
- SoldNUVAMA CROSSOVER OPPORTUNITIES FUND - SERIES IIISold 6,14,112 at ₹850.000.54% of the company₹52 Cr
- SoldNUVAMA CROSSOVER OPPORTUNITIES FUND - SERIES IIIABlock dealSold 5,62,360 at ₹850.000.50% of the company₹48 Cr
Friday 24 Jul 20266 firms · ₹320 Cr bought · ₹320 Cr soldNet nil
- BoughtSBI MUTUAL FUNDBlock dealBought 20,00,000 at ₹800.001.77% of the company₹160 Cr
- BoughtSBI MUTUAL FUNDBought 20,00,000 at ₹800.001.77% of the company₹160 Cr
- SoldNUVAMA CROSSOVER OPPORTUNITIES FUND - SERIES IIIBlock dealSold 10,60,000 at ₹800.000.94% of the company₹85 Cr
- SoldNUVAMA CROSSOVER OPPORTUNITIES FUND - SERIES IIISold 10,60,000 at ₹800.000.94% of the company₹85 Cr
- SoldNUVAMA CROSSOVER OPPORTUNITIES FUND - SERIES IIIABlock dealSold 9,40,000 at ₹800.000.83% of the company₹75 Cr
- SoldNUVAMA CROSSOVER OPPORTUNITIES FUND - SERIES IIIASold 9,40,000 at ₹800.000.83% of the company₹75 Cr
Friday 28 Nov 20256 firms · ₹503 Cr bought · ₹500 Cr soldNet bought ₹2.34 Cr
- Both waysJUNOMONETA FINSOL PRIVATE LIMITEDBought 19,75,787 at ₹768.67Sold 19,40,610 at ₹769.091.75% of the companyNet +35,177 shares₹152 Cr bought
- Both waysSHARE INDIA SECURITIES LIMITEDBought 6,53,366 at ₹747.90Sold 6,52,366 at ₹751.010.58% of the companyNet +1,000 shares₹49 Cr bought
- Both waysIRAGE BROKING SERVICES LLPBought 16,45,574 at ₹766.79Sold 16,45,574 at ₹767.271.46% of the companyNet nil₹126 Cr bought
- Both waysJUMP TRADING FINANCIAL INDIA PRIVATE LIMITEDBought 7,36,429 at ₹770.06Sold 7,36,429 at ₹770.560.65% of the companyNet nil₹57 Cr bought
- Both waysGOLDMINE STOCKS PRIVATE LIMITEDBought 8,17,793 at ₹769.97Sold 8,17,793 at ₹770.240.72% of the companyNet nil₹63 Cr bought
- Both waysGRT STRATEGIC VENTURES LLPBought 7,30,038 at ₹766.63Sold 7,30,038 at ₹766.930.65% of the companyNet nil₹56 Cr bought
A bulk deal is one client trading more than half a per cent of the shares in a day; a block deal is a large trade in the exchange's separate block window, its buyer and its seller each on a line of their own. A firm that bought and sold the shares the same day is on one line, with its net. All 25 deals on record since listing on 28 Nov 2025.